Skip to main content
Erschienen in: Clinical Drug Investigation 5/2004

01.05.2004 | Original Research Article

Cost of Heart Failure in Patients Receiving β-Blockers and Angiotensin-Converting Enzyme Inhibitors

verfasst von: Dr William S. Weintraub, Hugh Kawabata, Michele Tran, Gilbert J. L’italien, Roland S. Chen

Erschienen in: Clinical Drug Investigation | Ausgabe 5/2004

Einloggen, um Zugang zu erhalten

Abstract

Objective: Numerous studies support the benefit of β-blockers and angiotensin-converting enzyme inhibition (ACE-I) in the management of heart failure. However, the real-world cost of heart failure in patients who take these medications is not well documented; furthermore, it is unclear if heart failure costs remain significant when current, appropriately aggressive care is delivered.
Design: This study describes 1-year medical costs in patients hospitalised for heart failure who received these therapies, alone or in combination.
Methods: The study population was derived from 2.5 million patients with at least 3 years’ continuous eligibility in Pharmetrics®, an integrated claims and pharmacy database on approximately 25 million covered lives from 40 US health plans. The enrolment period was from 1 January 1996 to 31 December 2000. Costs included all recorded payments over a 1-year period. A total of 3073 patients (age >18 years) hospitalised with heart failure were identified (mean [± SD] age 72 ± 13 years; 46% female).
Results: The 1-year cost was $US16 786 in patients who received neither ACE inhibitors nor β-blockers as compared with $US19 567, $US22 785 and $US27 078 in patients who received ACE inhibitors, β-blockers or both drugs at maximum dosage, respectively (p < 0.001) [year of costing 2000]. Follow-up costs were substantial, representing almost twice the initial hospitalisation cost. Adjusted for age, sex, diabetes mellitus, coronary disease, hypertension and renal failure, costs remained significant in heart failure patients who received ACE inhibitors and/or β-blockers.
Conclusions: The 1-year cost of therapy for patients with heart failure is substantial, and there remains considerable need for more effective therapy to reduce the societal economic burden.
Literatur
1.
Zurück zum Zitat American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas (TX): American Heart Association, 2001 American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas (TX): American Heart Association, 2001
2.
Zurück zum Zitat Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure. Arch Intern Med 1999; 159: 1690–700PubMedCrossRef Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure. Arch Intern Med 1999; 159: 1690–700PubMedCrossRef
3.
Zurück zum Zitat Weintraub WS, Cole J, Tooley J. Cost and cost-effectiveness studies in heart failure research. Am Heart J 2002; 143: 565–76PubMedCrossRef Weintraub WS, Cole J, Tooley J. Cost and cost-effectiveness studies in heart failure research. Am Heart J 2002; 143: 565–76PubMedCrossRef
4.
Zurück zum Zitat Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting-enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–6PubMedCrossRef Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting-enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–6PubMedCrossRef
5.
Zurück zum Zitat LeJemtel TH, Sonnenblick EH, Frishman WH. Diagnosis and management of heart failure. In: Fuster V, Alexander RA, O’Rourke RA, et al., editors. Hurst’s the heart. New York: McGraw-Hill, 2001: 692–700 LeJemtel TH, Sonnenblick EH, Frishman WH. Diagnosis and management of heart failure. In: Fuster V, Alexander RA, O’Rourke RA, et al., editors. Hurst’s the heart. New York: McGraw-Hill, 2001: 692–700
6.
Zurück zum Zitat Weintraub WS, Krumholz H. Cost-effective strategies in cardiology. In: Fuster V, Alexander RW, O’Rourke RA, et al., editors. Hurst’s the heart. New York: McGraw-Hill, 2001: 2487–512 Weintraub WS, Krumholz H. Cost-effective strategies in cardiology. In: Fuster V, Alexander RW, O’Rourke RA, et al., editors. Hurst’s the heart. New York: McGraw-Hill, 2001: 2487–512
7.
Zurück zum Zitat Eisenberg SS. Benchmarking in understanding resource utilization and disease management: are we ready? Mining a large national database for supporting healthplan programs and activities using diabetes as a prototype. Dis Manag Health Outcomes 2001; 9 Suppl. 1: 29–38CrossRef Eisenberg SS. Benchmarking in understanding resource utilization and disease management: are we ready? Mining a large national database for supporting healthplan programs and activities using diabetes as a prototype. Dis Manag Health Outcomes 2001; 9 Suppl. 1: 29–38CrossRef
8.
Zurück zum Zitat Xuan J, Duong PT, Russo PA, et al. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000; 6: 693–700PubMed Xuan J, Duong PT, Russo PA, et al. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000; 6: 693–700PubMed
9.
Zurück zum Zitat Weintraub WS, Kawabata H, Tran M, et al. Influence of co-morbidity on cost of care for heart failure. Am J Cardiol 2003; 91: 1011–5PubMedCrossRef Weintraub WS, Kawabata H, Tran M, et al. Influence of co-morbidity on cost of care for heart failure. Am J Cardiol 2003; 91: 1011–5PubMedCrossRef
10.
11.
Zurück zum Zitat http/www.cms.gov [Accessed 2002 Aug 19] http/www.cms.gov [Accessed 2002 Aug 19]
12.
Zurück zum Zitat Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–5PubMedCrossRef Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–5PubMedCrossRef
13.
Zurück zum Zitat West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 1997; 79: 58–63PubMedCrossRef West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 1997; 79: 58–63PubMedCrossRef
14.
Zurück zum Zitat The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implatable defibrillators in patients resuscitated from near-fatal ventricular arrhythmicas. N Engl J Med 1997; 337: 1576–83CrossRef The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implatable defibrillators in patients resuscitated from near-fatal ventricular arrhythmicas. N Engl J Med 1997; 337: 1576–83CrossRef
15.
Zurück zum Zitat Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933–40PubMedCrossRef Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933–40PubMedCrossRef
16.
Zurück zum Zitat Auricchio A, Ding J, Spinelli JC, et al. Cardiac resynchronization therapy restores optimal atrioventricular mechanical timing in heart failure patients with ventricular conduction delay. J Am Coll Cardiol 2002; 39: 1163–9PubMedCrossRef Auricchio A, Ding J, Spinelli JC, et al. Cardiac resynchronization therapy restores optimal atrioventricular mechanical timing in heart failure patients with ventricular conduction delay. J Am Coll Cardiol 2002; 39: 1163–9PubMedCrossRef
17.
Zurück zum Zitat Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845–53PubMedCrossRef Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845–53PubMedCrossRef
18.
Zurück zum Zitat Hannan EL, Kilburn Jr H, Lindsey ML, et al. Clinical versus administrative data bases for CABG Surgery: does it matter? Med Care 1992; 30: 892–907PubMedCrossRef Hannan EL, Kilburn Jr H, Lindsey ML, et al. Clinical versus administrative data bases for CABG Surgery: does it matter? Med Care 1992; 30: 892–907PubMedCrossRef
19.
Zurück zum Zitat Weintraub WS, Deaton C, Shaw L, et al. Can cardiovascular clinical characteristics be identified and outcome models be developed from an in-patient claims database? Am J Cardiol 1999; 84: 166–9PubMedCrossRef Weintraub WS, Deaton C, Shaw L, et al. Can cardiovascular clinical characteristics be identified and outcome models be developed from an in-patient claims database? Am J Cardiol 1999; 84: 166–9PubMedCrossRef
Metadaten
Titel
Cost of Heart Failure in Patients Receiving β-Blockers and Angiotensin-Converting Enzyme Inhibitors
verfasst von
Dr William S. Weintraub
Hugh Kawabata
Michele Tran
Gilbert J. L’italien
Roland S. Chen
Publikationsdatum
01.05.2004
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 5/2004
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200424050-00002

Weitere Artikel der Ausgabe 5/2004

Clinical Drug Investigation 5/2004 Zur Ausgabe